Please login to the form below

Not currently logged in
Email:
Password:

Wyeth buys UK biotech company

Global pharmaceutical company Wyeth has announced it has acquired UK-based biotech Thiakis for approximately $30m

Global pharmaceutical company Wyeth has announced it has acquired UK-based biotech Thiakis for approximately $30m.

Thiakis was founded in 2004 and focuses on the development of novel medicines for the treatment of obesity. Under the terms of the deal, Wyeth will acquire Thiakis for approximately $30m, with additional payments up to $120m being made upon achievement of pre-specified milestones.

"This acquisition is evidence of our commitment to develop and bring to market innovative, high-value medicines that have the potential to address significant unmet needs in critical therapeutic areas such as metabolic disorders," said Dr Mikael Dolsten, president, Wyeth Research. 

"Thiakis' research and development programme fits well with our goal of addressing the medical burden of obesity in a targeted manner using biologic-based therapies."

Estimates from the World Health Organisation show that at least 300m people globally are obese. Excess body weight is a known factor in a number of conditions including Type 2 diabetes, stroke, cardiovascular disease and osteoarthritis.

30th December 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics